论文信息 - Macro trends in pharmaceutical innovation

Macro trends in pharmaceutical innovation

Critics decry the lack of 'truly innovative' new medicines and question the role of the pharmaceutical industry in creating the few that are developed. Is this an accurate portrayal of the state of pharmaceutical innovation? Does major pharma still innovate? If so, how? Must the industry innovate to survive? These and related issues are discussed.

Fredric Cohen | Fredric J. Cohen

[1] J. Reichert,et al. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. , 2003, Current opinion in molecular therapeutics.

[2] J. DiMasi,et al. Returns on R&D for 1990s New Drug Introductions: Charts , 2003 .

[3] Henry G. Grabowski,et al. Patents and new product development in the pharmaceutical and biotechnology industries , 2003 .

[4] Dror Ben-Asher. IN NEED OF TREATMENT? MERGER CONTROL, PHARMACEUTICAL INNOVATION, AND CONSUMER WELFARE , 2000, The Journal of legal medicine.

[5] F. Scherer,et al. The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.

[6] A. Wertheimer,et al. Too many drugs? The clinical and economic value of incremental innovations , 2001 .

[7] P. Roberts. Product innovation, product–market competition and persistent profitability in the U.S. pharmaceutical industry , 1999 .

[8] Irina Farquhar,et al. Investing in Health: The Social and Economic Benefits of Health Care Innovation , 2001 .

[9] A. McGahan,et al. How does innovative activity change as industries mature , 2001 .

[10] Amy M. Hightower,et al. Science and Engineering Indicators , 1993 .

[11] Henry G. Grabowski,et al. The Pharmaceutical Industry , 1982 .